Xuehai Liang, Ph.D
Biography
Dr. Xuehai Liang is Co-founder and CEO of Arnatar Therapeutics, Inc. He has more than 25 years of experience in RNA biology, antisense technology, and RNA-targeted drug discovery and development. Prior to founding Arnatar, Dr. Liang spent more than 12 years at Ionis Pharmaceuticals, where he served as Executive Director and led Core Antisense Research, advancing antisense mechanisms, oligonucleotide chemistry, and therapeutic discovery. His research spans RNA processing, RNA interference, oligonucleotide–protein interactions, and the development of RNA-targeted therapeutics for rare and common diseases, including liver-directed medicines. Dr. Liang has authored more than 100 scientific publications and is an inventor on more than 30 patents and patent applications. He received his Ph.D. from Bar-Ilan University and conducted subsequent research at the University of Massachusetts Amherst.
